Respiratory viruses do not discriminate, but older adults are at increased risk of respiratory tract infections. According to the CDC, most deaths from respiratory viruses occur in individuals over the age of 65, and the risk increases rapidly as age increases. 1
Therefore, vaccines for this population are extremely important. The first two RSV vaccines were approved in May 2023 2 , 3 and an additional vaccine, Moderna’s mRESVIA, was approved in May 2024 4 . Researchers are now beginning to evaluate the long-term effectiveness of these vaccines and vaccine uptake by age and demographics. , socio-economic factors, and whether a combination RSV vaccine targeting multiple lower respiratory tract threats is worth pursuing in clinical development.
Learn more about IDWeek here.
References Respiratory viruses and the elderly. CDC. Accessed October 17, 2024. https://www.cdc.gov/respiratory-viruses/risk-factors/older-socials.htmlBiscaldi L. Breaking: FDA approves first-ever RSV vaccine. drug topic. May 3, 2023. Accessed October 17, 2024. https://www.drugtopics.com/view/breaking-fda-approves-first-ever-rsv-vaccineFDA: Pfizer RSV vaccine approved for use in older adults. drug topic. June 1, 2023. Accessed October 17, 2024. https://www.drugtopics.com/view/fda-pfizer-rsv-vaccine-approved-for-use-in-older- AdultsBiscaldi L. Breaking News: FDA approves Moderna’s mRNA respiratory syncytial virus vaccine, mRESVIA. drug topic. May 31, 2024. Accessed October 17, 2024. https://www.drugtopics.com/view/breaking-fda-approves-moderna-s-mrna-rsv-vaccine-mresviaLa EM, McGuiness CB, Singer D, Yasuda M, et al. RSV vaccination rates among U.S. adults aged 60 and older at high risk for severe RSV disease (August 2023 to February 2024). Presentation location: IDWeek 2024; October 16-19, 2024. Los Angeles, California. Poster P-36.Walsh EE, Woodside J, Marc GP, et al. Efficacy of bivalent RSVpreF vaccine in older adults over the second period of RSV season. Presentation location: IDWeek 2024; October 16-19, 2024. Los Angeles, California. Poster P-600.Tartof SY, Ackerson B, Kapadia B, et al. Respiratory syncytial virus (RSV) vaccine uptake among adults aged 60 years and older in a large integrated health system in the United States. Presentation location: IDWeek 2024; October 16-19, 2024. Los Angeles, California. Poster P-56. Davis M, Shapiro C, Adams MD, et al. Safety and immunogenicity of a combination vaccine of respiratory syncytial virus and human metapneumovirus-like particle protein subunits in adults 60 to 85 years: Interim results from a phase 2a clinical trial. Presentation location: IDWeek 2024; October 16-19, 2024. Los Angeles, California. Poster P-601.
Source link
